Magaly Alonso, MD
Psychiatry · Miami, FLNPI 1861458226
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 34.9% of the total. 2025 is the largest year on record at $1,638, 2.5 times the $648 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$789
- Otsuka America Pharmaceutical, Inc.$782
- Neurocrine Biosciences, Inc.$757
- Lundbeck LLC$745
- Teva Pharmaceuticals USA, Inc.$558
- plus $2K from 15 others
Across 8 payments — averaging $110.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$885
What the payments were for
- Food & beverage$8,01499%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 148 | $2,816 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $789 |
| Otsuka America Pharmaceutical, Inc. | 38 | $782 |
| Neurocrine Biosciences, Inc. | 35 | $757 |
| Lundbeck LLC | 38 | $745 |
| Teva Pharmaceuticals USA, Inc. | 18 | $558 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $445 |
| Johnson & Johnson | 6 | $210 |
| Vanda Pharmaceuticals Inc. | 6 | $142 |
| Bausch Health US, LLC | 6 | $127 |
| Sunovion Pharmaceuticals Inc. | 9 | $110 |
| E.r. Squibb & Sons, L.L.C. | 4 | $103 |
| Eisai Inc. | 1 | $100 |
| Acadia Pharmaceuticals Inc | 1 | $91 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Tris Pharma Inc | 2 | $43 |
| Alkermes, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Livanova USA, Inc. | 1 | $33 |
| Noven Therapeutics, LLC | 1 | $23 |
| TMS Neurohealth Centers Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,058 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $112,814 |
| Lurasidone Hcl | 28 | $8,828 |
| FetzimaLevomilnacipran Hcl | 13 | $6,243 |
| Aripiprazole | 45 | $4,099 |
| Olanzapine | 36 | $4,079 |
| Buspirone Hcl | 115 | $1,203 |
| Mirtazapine | 127 | $1,127 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 76 | $1,071 |
| Trazodone Hcl | 181 | $1,017 |
| Duloxetine Hcl | 59 | $925 |
| Quetiapine Fumarate | 90 | $868 |
| Bupropion XlBupropion Hcl | 55 | $707 |
| Triazolam | 14 | $701 |
| Clonazepam | 208 | $615 |
| Escitalopram Oxalate | 72 | $546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $757 | $112,81414 claims |
| AbbVieFetzima | $2,816 | $6,24313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.